Akeso Biopharma is in a battle to defend the RMB130 level, with technical signals being 'neutral' and weaker than its peers; the success of the rebound depends on fund inflows.

In terms of biotech and innovative drug sectors, the market suffered a heavy blow yesterday (23rd). $AKESO (09926.HK)$

Plummeted 12.66%, $INNOVENT BIO (01801.HK)$ Dropped 5.90%, $WUXI BIO (02269.HK)$ Fell 3.14%,The sector saw widespread significant declines.

However, the technical signals showed high divergence and complexity: despite the sharp drop in stock prices,Innovent Bio, Wuxi BioThe technical indicator summary signal is 'Strong Buy,' indicating the system has determined it has entered a severely oversold region. In contrast, the comprehensive technical signal rating for Akeso Biopharma is 'Neutral,' but its overall rating is weaker than its peers, which may reflect individual factors (such as a large single-day drop, liquidity issues, or specific news impacts) leading to a more cautious evaluation by the system. $GENSCRIPT BIO (01548.HK)$ It is one of the few stocks in the sector with a clear 'Sell' signal and currently in an overbought condition.

This indicates that Akeso Biopharma's sharp decline occurred in an environment where the sector as a whole collapsed, but most stocks had already signaled extreme oversold conditions. Its 'Neutral' rating compared to the 'Strong Buy' signals of its peers suggests greater market divergence on its short-term outlook, with potentially lower rebound certainty than its peers, requiring stronger catalysts or capital inflows to reverse the downtrend.

Akeso Biopharma experienced a sharp drop last trading day (the 23rd), with market sentiment shifting rapidly from previously strong optimism to panic and caution. The most prominent comments were not about positive outlooks, but rather shock at the sudden large bearish candlestick. Many investors are asking what happened, whether the decline has ended, and if the current price is suitable for bottom fishing. Once a strongly rising stock, it suddenly became a focus due to the rapid drop, creating a significant emotional gap.

Overall market sentiment is clearly bearish, tinged with panic. Some investors believe the entire pharmaceutical sector is under pressure, but Akeso Biopharma’s drop was particularly large, raising doubts about the stock’s resilience. Others fear further declines, believing a short-term bottom has not yet been reached. While a small number of voices have begun planning orders or considering technical rebounds, the dominant sentiment remains cautious, risk-averse, and even powerless after being disrupted by the sharp fall.

Common questions mainly focus on three aspects:

First, what caused this sharp decline?

Second, can the support near HKD 130 hold?

Third, is the current price worth buying for a potential rebound?

These questions all point to the same core issue: whether the structure post-sharp decline has been broken and whether support levels can hold.

From a technical perspective, Akeso Biopharma closed at HKD 130.4 yesterday, having risen sharply from its previous low to a peak of HKD 156, initially showing clear strength. However, following the large bearish candlestick plunge, it broke below the 5-day, 10-day, and 20-day moving averages, retreating close to the 30-day line, indicating that the short-term uptrend has been significantly disrupted, with momentum turning weak. The Relative Strength Index dropped to 29.92, reflecting a rapid deterioration in short-term momentum. The middle band of the Bollinger Bands sits at HKD 137.125, and the current price is notably below it, showing heavy selling pressure and a lack of market stability.

At this stage, the most critical watershed is at HKD 130. The stock price has approached the 30-day line at HKD 129.763 and the support level at HKD 130, which might trigger a short-term technical rebound. However, as long as it fails to break through HKD 147 again, the overall trend should still be considered a recovery after a sharp decline, not a true strengthening. If the support at HKD 130 is broken, the next key level to watch will be the support at HKD 125.31, where the overall weakness could deepen further. Therefore, the current risk-reward ratio remains neutral to low, not because of insufficient volatility, but because the probability of successfully chasing a rebound remains relatively low after the structure has been disrupted.

Reply to some investors' views:

@慷慨的卡桑德拉This large bearish candle has already significantly disrupted the original uptrend; it requires re-evaluation in the short term.

@Johnny’s Alpha LogAfter a major drop, there will likely be some short-term rebound capital, but whether it can be captured depends on the strength of support around HKD 130.

@小丑的逆袭The area near HKD 130 is indeed a dangerous zone and also the most important short-term defense line.

Based on the above analysis, the strategies for deployment can be divided into the following main approaches:

$SGAKESO@EC2608A.C (25883.HK)$$BIAKESO@EC2608A.C (25994.HK)$

For more market analysis, stay tuned to Jenny's daily updates on 'Hong Kong Stock Warrants'!

Reminder: This article does not constitute any investment advice.

This article is for reference only and does not constitute any investment advice. The market data, opinions, and analysis contained herein may change at any time without prior notice. We are not responsible for any loss or damage caused by reliance on the information in this article. Technical analysis only shows whether certain technical conditions are met; a comprehensive assessment of asset performance should be conducted using additional data. Decisions to trade should not be based solely on this article. Please note that past performance is not indicative of future results.

#HKStocks #CansinoBiologics #Real-TimeAnalysis #WarrantPick #WarrantGuide #DerivativesHedging #HKWarrantsJenny #Blue-ChipStocks #TechnicalAnalysis

$Hang Seng Index (800000.HK)$ $Hang Seng China Enterprises Index (800100.HK)$ $Hang Seng TECH Index (800700.HK)$

106K Views